<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01118312</url>
  </required_header>
  <id_info>
    <org_study_id>ALAACRC-11</org_study_id>
    <secondary_id>R01 HL089464-01A2</secondary_id>
    <secondary_id>R01 HL00895101-01A2</secondary_id>
    <nct_id>NCT01118312</nct_id>
  </id_info>
  <brief_title>Study of Asthma and Nasal Steroids</brief_title>
  <acronym>STAN</acronym>
  <official_title>Study of Asthma and Nasal Steroids for the American Lung Association-Airways Clinical Research Centers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHSPH Center for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>JHSPH Center for Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will study the effectiveness of nasal steroids for the treatment of chronic
      rhinitis and/or sinusitis on asthma control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous trials completed by the American Lung Association-Airways Clinical Research Centers
      (ALA-ACRC) network have identified rhinitis and/or sinusitis as a significant co-morbidity in
      people with asthma that affects asthma symptoms and control. The objective of this clinical
      trial is to determine if treatment of chronic rhinitis and/or sinusitis with nasal steroids
      improves control of asthma in children and adults. Although chronic rhinitis and/or sinusitis
      have been associated with poor asthma control and increased health care utilization, the
      effect of treating these diseases on asthma control is not known. This will be a six-month
      randomized, double-blinded, placebo-controlled trial enrolling 380 participants, 190 children
      and 190 adults, with poorly controlled asthma and chronic rhinitis/sinusitis. Participants
      will be randomized to receive nasal steroid or a matching placebo in addition to their
      regular asthma treatments. The primary objective of the trial will be to evaluate whether the
      addition of treatment with nasal steroids improves asthma control. We will perform allergy
      skin testing on all participants and keep a record of pollen counts at all centers, to
      determine if allergy is an important factor in the response to nasal steroid in participants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Control Test (ACT)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Asthma Control Test for adults (score range: 5-25); higher score indicates better asthma control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Childhood Asthma Control Test</measure>
    <time_frame>24 weeks</time_frame>
    <description>Childhood Asthma Control Test (score range: 0-27); higher score indicates better asthma control</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">388</enrollment>
  <condition>Asthma</condition>
  <condition>Rhinitis</condition>
  <condition>Sinusitis</condition>
  <arm_group>
    <arm_group_label>Nasal Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal mometasone, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intranasal placebo, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate monohydrate</intervention_name>
    <description>Intranasal mometasone, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day for 6 months</description>
    <arm_group_label>Nasal Steroid</arm_group_label>
    <other_name>Nasonex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intranasal placebo spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physician diagnosed asthma

          -  At least 12% increase in forced expiratory volume at one second (FEV1) after 2-4 puffs
             of albuterol or positive methacholine challenge (20% fall in FEV1 at less than 16
             mg/ml methacholine); either of these can be available from the last 2 years before
             enrollment

          -  Poorly controlled asthma as documented by a score of 19 or less on the Asthma Control
             Test (ACT) for participants 12 and older, and a Childhood Asthma Control Test (C-ACT)
             for 6-11 years(both V1 and V2).

          -  Chronic symptoms of rhinitis and sinusitis as measured by a mean score of 1 on the
             Sino-nasal questionnaire

          -  Males and females, age 6 and older

        Exclusion Criteria:

          -  Co-morbidity that predisposes to complicated rhino-sinusitis (e.g., cystic fibrosis,
             insulin dependent diabetes mellitus, immunodeficiency disorder)

          -  Chronic diseases (other than asthma) that in the opinion of the investigator would
             prevent participation in the trial or put the participant at risk by participation,
             e.g. chronic diseases of the lung (other than asthma), heart, liver, kidney or nervous
             system.

          -  History of sinus surgery in last 6 months

          -  Systemic/nasal steroids within last 4 weeks

          -  Anti-leukotriene medication

          -  History of upper airway symptoms for less than 8 weeks at the time of enrollment

          -  Fever &gt; 38.3 degrees Celsius or patient history of fever in last 10 days

          -  Greater than 10 pack year smoking history or active smoking within the last 6 months

          -  FEV1 &lt; 50% predicted

          -  Females of childbearing potential that are pregnant or lactating, or unwilling to
             practice an adequate birth control method

          -  Allergy or intolerance to nasal mometasone

          -  Cataracts, history of glaucoma, or other conditions resulting in increased intraocular
             pressure

          -  Any investigational drug in the last 6 weeks

          -  Inability to comply with study procedures, including:

               -  Inability or unwillingness to provide informed consent (or assent in the case of
                  a minor)

               -  Inability to take study medication

               -  Inability to perform baseline measurements

               -  Completion of less than 10 of the 14 days of screening period diary entry

               -  Inability to be contacted by phone

               -  Intention to move out of the area within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Dixon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida College of Medicine</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri, Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore-Long Island Jewish Health System</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davis Heart and Lung Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Lung Center at the University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cctrials.org/alaacrc</url>
    <description>ALA-ACRC Webpage</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2010</study_first_submitted>
  <study_first_submitted_qc>May 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2010</study_first_posted>
  <results_first_submitted>September 24, 2015</results_first_submitted>
  <results_first_submitted_qc>October 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 30, 2015</results_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Rhinitis</keyword>
  <keyword>Sinusitis</keyword>
  <keyword>Chronic</keyword>
  <keyword>ACRC</keyword>
  <keyword>STAN</keyword>
  <keyword>Nasal steroid</keyword>
  <keyword>Mometasone</keyword>
  <keyword>Nasal spray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nasal Steroid</title>
          <description>Intranasal mometasone, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day
Mometasone Furoate monohydrate: Intranasal mometasone, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Intranasal placebo, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day
Placebo: Intranasal placebo spray</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nasal Steroid</title>
          <description>Intranasal mometasone, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day
Mometasone Furoate monohydrate: Intranasal mometasone, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Intranasal placebo, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day
Placebo: Intranasal placebo spray</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="189"/>
            <count group_id="B2" value="199"/>
            <count group_id="B3" value="388"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Asthma Control Test (ACT)</title>
        <description>Asthma Control Test for adults (score range: 5-25); higher score indicates better asthma control</description>
        <time_frame>24 weeks</time_frame>
        <population>Analysis of adult (18 and above) Asthma Control Scores</population>
        <group_list>
          <group group_id="O1">
            <title>Nasal Steroid</title>
            <description>Intranasal mometasone, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day
Mometasone Furoate monohydrate: Intranasal mometasone, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intranasal placebo, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day
Placebo: Intranasal placebo spray</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Test (ACT)</title>
          <description>Asthma Control Test for adults (score range: 5-25); higher score indicates better asthma control</description>
          <population>Analysis of adult (18 and above) Asthma Control Scores</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" spread="0.31"/>
                    <measurement group_id="O2" value="2.44" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Childhood Asthma Control Test</title>
        <description>Childhood Asthma Control Test (score range: 0-27); higher score indicates better asthma control</description>
        <time_frame>24 weeks</time_frame>
        <population>Analysis of Children (less than 18 years old) Childhood Asthma Control Test scores</population>
        <group_list>
          <group group_id="O1">
            <title>Nasal Steroid</title>
            <description>Intranasal mometasone, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day
Mometasone Furoate monohydrate: Intranasal mometasone, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intranasal placebo, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day
Placebo: Intranasal placebo spray</description>
          </group>
        </group_list>
        <measure>
          <title>Childhood Asthma Control Test</title>
          <description>Childhood Asthma Control Test (score range: 0-27); higher score indicates better asthma control</description>
          <population>Analysis of Children (less than 18 years old) Childhood Asthma Control Test scores</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" spread="0.64"/>
                    <measurement group_id="O2" value="4.53" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nasal Steroid</title>
          <description>Intranasal mometasone, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day
Mometasone Furoate monohydrate: Intranasal mometasone, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Intranasal placebo, 1 spray (age &lt; 12 yr) or 2 sprays (age &gt;= 12 yrs) each nostril once a day
Placebo: Intranasal placebo spray</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Dental abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression (hospitalized)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Fungus ball of the sinus requiring surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Headache and high blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="179"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizzy</sub_title>
                <description>Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>Nasal bleed</sub_title>
                <description>Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Nasal pain</sub_title>
                <description>Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <description>Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Trouble breathing</sub_title>
                <description>Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <description>Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Razan Yasin</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>443-287-5796</phone>
      <email>ryasin1@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

